论文部分内容阅读
目的:探讨胃癌患者sCD44v6术前水平与不同的组织学参数之间及与中医证型之间的关系,同时观察胃泰胶囊结合化疗对sCD44v6表达的影响。方法:全部入组病例在术前行中医证型分组及治疗前后行sCD44v6检测;对照组在术后3-4周均接受3～4个周期静脉化疗。试验组术后在对照组治疗基础上予以胃泰胶囊,4粒,3/日,口服,连服3个月。结果:1)血清sCD44v6水平与胃癌分化程度、浸润深度及淋巴结转移呈显著正相关。2)sCD44v6水平血瘀证最高,和脾虚证、湿热证相比有非常显著差异。3)结束治疗后试验组血清sCD44v6含量明显低于对照组。结论:1)血清sCD44v6可作为胃癌的发展、预后指标,同时也可以作为抗胃癌转移的治疗靶标。2)血清sCD44v6和血瘀证、脾虚证存在着一定的相关性。3)胃泰胶囊配合化疗能够进一步抑制胃癌患者血清sCD44v6的表达。
Objective: To investigate the relationship between sCD44v6 preoperative levels and different histological parameters in gastric cancer patients and TCM syndromes, and to observe the effect of Weitai capsule combined with chemotherapy on sCD44v6 expression. Methods: All the patients were examined with sCD44v6 before and after the treatment of TCM syndromes before and after the operation. The patients in the control group received 3 ~ 4 cycles of intravenous chemotherapy 3-4 weeks postoperatively. The experimental group was treated with Weitai Capsule on the basis of the control group after operation for 4 months, 3 days per day for 3 months. Results: 1) Serum levels of sCD44v6 were significantly and positively correlated with the degree of differentiation, depth of invasion and lymph node metastasis. 2) The highest level of sCD44v6 blood stasis, and spleen deficiency syndrome, damp-heat syndrome compared to a very significant difference. 3) After treatment, serum sCD44v6 level in the experimental group was significantly lower than that in the control group. Conclusion: 1) Serum sCD44v6 can be used as a marker for the development and prognosis of gastric cancer, and it can also be used as a therapeutic target against gastric cancer metastasis. 2) serum sCD44v6 and blood stasis, spleen deficiency there is a certain correlation. 3) Weitai capsule combined with chemotherapy can further inhibit the expression of sCD44v6 in patients with gastric cancer.